These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 120380

  • 1. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
    Mojamdar M, Ichihashi M, Mishima Y.
    J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
    [No Abstract] [Full Text] [Related]

  • 2. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T, Tatsumi F, Fukada E, Saito M, Fujita M, Nagashima N, Hanawa S.
    Arch Dermatol Res; 1983 Dec; 275(2):76-9. PubMed ID: 6409012
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G, Agrup P, Andersson T, Falck B, Hansson JA, Jacobsson S, Rorsman H, Rosengren E, Rosengren AM.
    Acta Derm Venereol; 1977 Dec; 57(2):113-6. PubMed ID: 71802
    [Abstract] [Full Text] [Related]

  • 5. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G, Agrup P, Andersson T, Hafström L, Hansson C, Jacobsson S, Jönsson PE, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1979 Dec; 59(5):381-8. PubMed ID: 93360
    [Abstract] [Full Text] [Related]

  • 6. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M, Mojamdar M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Inoi T, Mojamdar M, Ichihashi M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
    [No Abstract] [Full Text] [Related]

  • 10. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
    Beyer C, Fiedler H, Wohlrab W, Wozniak KD.
    Dermatol Monatsschr; 1986 Sep; 172(9):541-4. PubMed ID: 3098590
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
    Sameshima T, Morishima T.
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
    Nixon PF.
    Aust N Z J Surg; 1978 Feb; 48(1):17-21. PubMed ID: 276342
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
    Aubert C, Rosengren E, Rorsman H, Rouge F, Foa C, Lipcey C.
    Eur J Cancer (1965); 1977 Nov; 13(11):1299-308. PubMed ID: 590287
    [No Abstract] [Full Text] [Related]

  • 18. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V, Paul E.
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.